5.21
price down icon4.23%   -0.23
pre-market  プレマーケット:  5.19   -0.02   -0.38%
loading
前日終値:
$5.44
開ける:
$5.36
24時間の取引高:
1.65M
Relative Volume:
1.91
時価総額:
$102.21M
収益:
$146.07M
当期純損益:
$-196.04M
株価収益率:
-0.3135
EPS:
-16.621
ネットキャッシュフロー:
$-75.37M
1週間 パフォーマンス:
-37.98%
1か月 パフォーマンス:
-48.36%
6か月 パフォーマンス:
-21.77%
1年 パフォーマンス:
-6.96%
1日の値動き範囲:
Value
$5.095
$5.71
1週間の範囲:
Value
$5.095
$9.04
52週間の値動き範囲:
Value
$3.51
$10.99

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name
名前
Karyopharm Therapeutics Inc
Name
セクター
Healthcare (1114)
Name
電話
617-658-0600
Name
住所
85 WELLS AVENUE, NEWTON, MA
Name
職員
228
Name
Twitter
@Karyopharm
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
KPTI's Discussions on Twitter

Compare KPTI vs VRTX, REGN, ALNY, ARGX, INSM

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
KPTI icon
KPTI
Karyopharm Therapeutics Inc
5.21 106.72M 146.07M -196.04M -75.37M -16.62
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 115.58B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 79.23B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 43.59B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 43.26B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 31.97B 606.42M -1.28B -997.58M -6.403

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-10 開始されました Rodman & Renshaw Buy
2026-02-05 開始されました Cantor Fitzgerald Overweight
2025-10-13 アップグレード H.C. Wainwright Neutral → Buy
2025-07-16 ダウングレード H.C. Wainwright Buy → Neutral
2025-07-11 再開されました H.C. Wainwright Buy
2023-01-19 開始されました Piper Sandler Overweight
2022-11-04 アップグレード RBC Capital Mkts Sector Perform → Outperform
2022-02-09 アップグレード JP Morgan Underweight → Neutral
2021-11-19 再開されました Morgan Stanley Equal-Weight
2021-08-06 ダウングレード JP Morgan Overweight → Neutral
2021-08-06 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-08-06 ダウングレード SVB Leerink Outperform → Mkt Perform
2020-07-02 開始されました Morgan Stanley Overweight
2020-03-04 開始されました Barclays Overweight
2020-01-17 ダウングレード Wedbush Outperform → Neutral
2019-07-23 アップグレード JP Morgan Neutral → Overweight
2019-07-05 繰り返されました H.C. Wainwright Buy
2019-07-05 繰り返されました Robert W. Baird Outperform
2019-03-01 ダウングレード JP Morgan Overweight → Neutral
2019-02-28 繰り返されました BofA/Merrill Underperform
2019-02-27 ダウングレード BofA/Merrill Neutral → Underperform
2019-01-03 アップグレード BofA/Merrill Underperform → Neutral
2018-12-03 開始されました B. Riley FBR Buy
2018-11-09 アップグレード Wedbush Neutral → Outperform
2018-05-24 ダウングレード Wedbush Outperform → Neutral
2018-04-02 再開されました Leerink Partners Outperform
2017-11-15 再開されました H.C. Wainwright Buy
2017-09-15 開始されました RBC Capital Mkts Outperform
2016-09-08 繰り返されました H.C. Wainwright Buy
2016-08-30 アップグレード Jefferies Hold → Buy
2016-08-18 開始されました H.C. Wainwright Buy
2016-06-28 開始されました Robert W. Baird Outperform
すべてを表示

Karyopharm Therapeutics Inc (KPTI) 最新ニュース

pulisher
Mar 25, 2026

KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data - TradingView

Mar 25, 2026
pulisher
Mar 25, 2026

KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN

Mar 25, 2026
pulisher
Mar 25, 2026

KPTI: Baird Lowers Price Target, Maintains Outperform Rating | K - GuruFocus

Mar 25, 2026
pulisher
Mar 25, 2026

Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $15.00 at Robert W. Baird - MarketBeat

Mar 25, 2026
pulisher
Mar 25, 2026

HC Wainwright Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $8.00 - MarketBeat

Mar 25, 2026
pulisher
Mar 25, 2026

H.C. Wainwright cuts Karyopharm stock price target on trial results By Investing.com - Investing.com Canada

Mar 25, 2026
pulisher
Mar 25, 2026

HC Wainwright & Co. Lowers Price Target on Karyopharm Therapeuti - GuruFocus

Mar 25, 2026
pulisher
Mar 25, 2026

Karyopharm raises $30M in private placement with RA Capital By Investing.com - Investing.com Australia

Mar 25, 2026
pulisher
Mar 25, 2026

Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in MyelofibrosisSlideshow (NASDAQ:KPTI) 2026-03-25 - Seeking Alpha

Mar 25, 2026
pulisher
Mar 25, 2026

Karyopharm myeloma drug yields mixed data in myelofibrosis trial - BioPharma Dive

Mar 25, 2026
pulisher
Mar 24, 2026

Karyopharm’s myelofibrosis trial meets one of two primary goals By Investing.com - Investing.com India

Mar 24, 2026
pulisher
Mar 24, 2026

KPTI Shares Fall Following Varied Results from Phase III Myelofibrosis Combination Study - Bitget

Mar 24, 2026
pulisher
Mar 24, 2026

Why Is Karyopharm Therapeutics Stock Trading Lower Today?Karyopharm Therapeutics (NASDAQ:KPTI) - Benzinga

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm’s Phase 3 SENTRY Trial Shows Significant Spleen Reduction and Promising Overall Survival in Myelofibrosis with Selinexor Plus Ruxolitinib 1 - Minichart

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm phase III Sentry entry bucks rux in MF; to FDA next - BioWorld MedTech

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm, looking to jump-start Xpovio, reports mixed results in myelofibrosis - Fierce Pharma

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm research and financing developments - The Pharma Letter

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm shares rise 10% after mixed Phase 3 SENTRY trial results - MSN

Mar 24, 2026
pulisher
Mar 24, 2026

KPTI Stock Faces Uncertainty Amid Financial Challenges - StocksToTrade

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm Therapeutics SENTRY Trial Hits Spleen Endpoint, Shows Early Survival Signal in Myelofibrosis - MarketBeat

Mar 24, 2026
pulisher
Mar 24, 2026

RBC Capital maintains Outperform on Karyopharm stock after trial data By Investing.com - Investing.com Canada

Mar 24, 2026
pulisher
Mar 24, 2026

RBC Capital maintains Outperform on Karyopharm stock after trial data - Investing.com

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm Therapeutics (KPTI) Stock Plunges 12.71% on $30M Financing Announcement - Blockonomi

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm (KPTI) Announces Positive Phase 3 Trial Results for S - GuruFocus

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm Therapeutics Inc. (KPTI) Stock: Drops 12.71% After $30M Private Placement Deal - CoinCentral

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm Shares Jump 10% Following Mixed Phase 3 Trial Outcomes on Myelofibrosis Treatment - StockInvest.us

Mar 24, 2026
pulisher
Mar 24, 2026

Why Did KPTI Stock Tank 13% In Pre-Market Today? - Stocktwits

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm Therapeutics (KPTI) Secures $30M in Private Placement, Stock Soars - GuruFocus

Mar 24, 2026
pulisher
Mar 24, 2026

KPTI: Selinexor plus ruxolitinib nearly doubled spleen response and improved survival in myelofibrosis - TradingView

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm Therapeutics Secures $30M Private Placement with RA Capital Management - citybiz

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm Announces Financing and Positive SENTRY Trial Results - TipRanks

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm (KPTI) Shares Surge After Positive Selinexor Trial Re - GuruFocus

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm Therapeutics Raises ~$30 Million in RA Capital Private Placement, $44 Million Warrant Upside - TradingView

Mar 24, 2026
pulisher
Mar 24, 2026

SENTRY myelofibrosis data and $30M private placement reshape Karyopharm (NASDAQ: KPTI) - Stock Titan

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm posts trial win for Xpovio in myelofibrosis (KPTI) - Seeking Alpha

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm (KPTI) Announces $30M Private Placement Deal - GuruFocus

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm stock gains 10% on mixed Phase 3 trial data - Investing.com UK

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm stock gains 10% on mixed Phase 3 trial data By Investing.com - Investing.com South Africa

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm raises $30M in private placement with RA Capital - Investing.com

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study - TradingView

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm Therapeutics announces topline results from Phase 3 SENTRY trial in myelofibrosis - Traders Union

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction - Karyopharm

Mar 24, 2026
pulisher
Mar 24, 2026

Karyopharm Announces $30 Million Private Placement with RA Capital - PR Newswire

Mar 24, 2026
pulisher
Mar 24, 2026

New myelofibrosis drug combo shrank spleens in half of patients - Stock Titan

Mar 24, 2026
pulisher
Mar 22, 2026

How The Selinexor Story Is Reframing Karyopharm Therapeutics (KPTI) And Its Growth Expectations - Yahoo Finance

Mar 22, 2026
pulisher
Mar 20, 2026

Karyopharm Therapeutics Inc.: Fundamental Analysis and Financial Ratings | | US48576U2050 - marketscreener.com

Mar 20, 2026
pulisher
Mar 20, 2026

Profit Recap: How sensitive is Karyopharm Therapeutics Inc to inflationShort Setup & Long-Term Safe Investment Plans - baoquankhu1.vn

Mar 20, 2026
pulisher
Mar 19, 2026

Myelofibrosis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Galecto Biotech, Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Mye - StreetInsider

Mar 19, 2026
pulisher
Mar 19, 2026

KPTI SEC FilingsKaryopharm Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

Stock Traders Purchase Large Volume of Call Options on Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat

Mar 19, 2026

Karyopharm Therapeutics Inc (KPTI) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
大文字化:     |  ボリューム (24 時間):